Security key
00847X104
AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO)
CUSIP: 00847X104
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Total 13F shares
- 59,963,279
- Total 13F value
- $1,757,322,194
- Share change
- +212,062
- Put/Call ratio
- 112%
- SEC-reported price per share
- $29.30
- Number of holders
- 216
- Value change
- -$10,187,060
- Number of buys
- 107
- Number of sells
- 114
- Shares outstanding
- 59,771,717
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
216
Top holders
10
AGIO full security history
Ownership snapshot
Full 13F holder table
AGIOS PHARMACEUTICALS, INC. SEC filings
AGIOS PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FARALLON CAPITAL MANAGEME...
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
Lead comparable stake: 9.5%
Showing 1-6 of 15 holder rows.
Quick read
FARALLON CAPITAL MANAGEMENT, L.L.C. leads the comparable SEC ownership view at 9.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FARALLON CAPITAL MANAGEMENT, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
FARALLON CAPITAL MANAGEMENT, L.L.C.
9.5%
VANGUARD GROUP INC
9.4%
BlackRock, Inc.
8.4%
Bellevue Group AG
5.9%
PRICE T ROWE ASSOCIATES INC /MD/
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
9.5%
|
$186,462,953
5,674,466 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
9.4%
|
$185,045,209
5,631,321 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
8.4%
|
$164,834,303
5,016,260 shares
|
— | 31 Dec 2024 |
| Bellevue Group AG |
13F
Company
|
5.9%
|
$115,507,829
3,515,150 shares
|
— | 31 Dec 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
4.1%
|
$79,639,000
2,423,537 shares
|
— | 31 Dec 2024 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
3.8%
|
$74,405,029
2,264,304 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
216
Shares
59,963,279
Rows available
216
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
216
Q1 2025 holders
216
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|